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Abstract
Background: Antiretroviral therapy (ART) is a lifesaver for individual patients treated for Human Immunodeficiency Virus
(HIV) and Acquired Immune Deficiency Syndrome (AIDS). Maintaining optimal adherence to antiretroviral drugs is essential
for HIV infection management. This study aimed to understand the factors influencing adherence amongst ART-prescribed
patients and care providers in Nepal.
Methods: A cross-sectional mixed-methods study surveying 330 ART-prescribed patients and 34 in-depth interviews with
three different types of stakeholders: patients, care providers, and key people at policy level. Adherence was assessed
through survey self-reporting and during the interviews. A multivariate logistic regression model was used to identify
factors associated with adherence, supplemented with a thematic analysis of the interview transcripts.
Results: A total of 282 (85.5%) respondents reported complete adherence, i.e. no missed doses in the four-weeks prior to
interview. Major factors influencing adherence were: non-disclosure of HIV status (OR= 17.99, p = 0.014); alcohol use
(OR= 12.89, p =,0.001), being female (OR= 6.91, p = 0.001), being illiterate (OR= 4.58, p = 0.015), side-effects (OR= 6.04,
p = 0.025), ART started #24 months (OR = 3.18, p = 0.009), travel time to hospital .1 hour (OR = 2.84, p = 0.035). Similarly,
lack of knowledge and negative perception towards ART medications also significantly affected non-adherence. Transport
costs (for repeat prescription), followed by pills running out, not wanting others to notice, side-effects, and being busy were
the most common reasons for non-adherence. The interviews also revealed religious or ritual obstacles, stigma and
discrimination, ART-associated costs, transport problems, lack of support, and side-effects as contributing to non-adherence.
Conclusion: Improving adherence requires a supportive environment; accessible treatment; clear instructions about
regimens; and regimens tailored to individual patients’ lifestyles. Healthcare workers should address some of the practical
and cultural issues around ART medicine whilst policy-makers should develop appropriate social policy to promote
adherence among ART-prescribed patients.
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Introduction
The advent of antiretroviral treatment (ART) has dramatically
slowed down the progression of HIV, reduced the death rate from
AIDS and transformed the infection from a fatal illness to a more
manageable chronic illness [1,2]. Since 2004, Nepal has been
providing free-of-cost ART and by the end of 2009, over 2,524
adults received free ART at 23 sites across the country out of an
estimated over 63,528 People Living with HIV (PLHIV) nationally
[3]. The success of a national scale-up of ART depends on
bolstering the capacity of the health care system and shifting its
orientation from acute care to a chronic-care model [4,5].
However, simply making ART medicine available to PLHIV is
not enough, as strict adherence is required for treatment success
[2,6]. Poor adherence can lead to the virological failure of cheap
first-line treatment regimens and the spread of multi-drug resistant
forms of the virus, resulting in a public health calamity [2,7,8].
Unlike many other diseases, it is vital that PLHIV consume all
doses of the drug to prevent resistance and to improve their
chances of survival. Understanding the level of non-adherence and
the factors that lead to it are important clinical and public health
goals. This information is essential to inform ART programmes
and maximise the success of treatment.
Paterson and colleagues found that adherence greater than 95%
is needed to achieve virological success; however 22% of patients
with an adherence level of over 95% experienced virological
failure (i.e. a sharp increase in viral load) compared to 61% of
patients with adherence between 80–94.9%, and 80% of patients
with an adherence level of below 80% [2]. A meta-analysis
of studies of ART adherence found that a pooled estimate of 77%
of patients in Africa achieved adequate adherence (.95% of
prescribed pills) compared to just 55% of patients in North
America [9]. However, the relationship between adherence and
the development of resistance differs by regimens; for example
resistance to non-nucleoside reverse transcriptase inhibitors is
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significantly higher at low levels of adherence than that for
protease inhibitors [10].
Prescribers hope that every patient completely follows their
ART instructions, but the literature shows that a proportion of
PLHIV do not take medications as prescribed for various reasons.
A patient’s ability to adhere to medication is greatly influenced by
both individual and environmental factors. Several studies have
shed light on the factors affecting adherence, highlighting socio-
demographic, cultural, economic, health-systems and treatment-
related factors [9,11,12]. Many barriers to adherence are common
to both developed and developing countries such as fear of
disclosure [9]. However, some are more common in the Asian
developing countries such as ART-associated costs (transport fares,
diagnostic costs) and problems with travel to access treatment [13].
Hence, to benefit from ART, it is important to identify adherence
behaviour, understand the conditions that lead to non-adherence
and develop strategies and social policies to maximise long-term
adherence. This study was designed to identify the current levels of
adherence and the factors influencing adherence to ART in Nepal,
as to our knowledge, there is no prior study of this kind in Nepal.
Methods
A cross-sectional mixed-methods study was conducted in late
2009. It included a quantitative survey with 330 ART prescribed
patients from ten ART sites across Nepal and qualitative in-depth
interviews with 34 purposively selected participants, namely 17
ART-prescribed patients, 14 ART service providers (including
doctors, nurses, paramedics), and three policy-makers.
For the survey eligible respondents were taken from a daily
hospital visit schedule using a systematic random sampling
technique [14]. Adherence was assessed by using a self-reported
Adult AIDS Clinical Trial Groups (AACTG) adherence instru-
ment [15], originally developed in the United States and now
widely adopted in many countries [16,17]. In addition to the
AACTG questionnaire, a further structured questionnaire was
developed from the literature. The dependent variable was
‘adherence to ART’, independent variables were socio-demo-
graphic and cultural, health condition, and service facility,
knowledge, and perception of ART treatment related variables.
Patients were considered adherent when they took 100% (not
missing a single dose of ART) based on self-report in a four-week
recall prior to the study; otherwise, they were categorized as non-
adherent. If they reported having missed or skipped a dose during
that time, the questionnaire asked a range of multiple-choice
questions about why they had missed their pills.
Logistic regression analysis was performed to examine the
effects of explanatory ( = independent) variables on adherence. All
variables, both explanatory and dependent, were coded as binary
variables prior to fitting in the model; for adherence this meant
that 0= non-adherent and 1= adherent. Initially, explanatory
variables were included in the model one at a time to examine
their univariate relationship with adherence. As many variables
were analysed, only those that were significant are presented.
Following on from this univariate analysis, multiple logistic
regressions was used to model the effects of many variables
simultaneously. Variables were fitted in the model in blocks: 1)
socio-demographic and cultural; 2) health condition; 3) health-
service facility; 4) knowledge; and 5) perception related variables.
At each stage, the least significant variable was excluded until the
model contained only statistically significant factors. Statistical
analyses were conducted using the Statistical Package for the
Social Science (SPSS) version 17.0 and a p-value of less than 0.05
was used to define statistical significance.
The in-depth interviews were conducted with the aid of an
interview checklist and probes for further questioning [14],
covering questions on how ART fitted into their daily routines
and what key factors were impeding their adherence to their
medication. The interviews were conducted and audiotaped in
Nepali by the first author who is a native speaker; sessions lasted
1–1K hours. Audio recordings were transcribed verbatim in
Nepali and then translated into English. Data were organized
using NVivo version 8 [18] and coded using a thematic analysis
[19]. The quotations included below best represented the range of
ideas voiced around key themes; to maintain anonymity these
quotes are identified by gender and region only. For the same
reason, nurses and paramedics are all coded as ‘counsellor’. To
assure quality of the data, the main survey questionnaire was
piloted [20] with 15 selected ART prescribed patients and the
semi-structured questionnaire (checklist) was piloted with two
patients on ART and a care provider; subsequently some
modifications were incorporated in the research instruments.
Ethical permission for the study was obtained from the Nepal
Health Research Council. Individual consent was sought before
interviews, often in the form of oral consent as about 42% of the
population in Nepal is illiterate [21].
Results
Quantitative Results
In total 330 ART prescribed patients were approached and
100% responded to the main questionnaire; a total of 57.0% were
male and the mean age was 35.8 (SD 8.30) years (range 18 to 62).
The majority (70%) of the respondents were married, 38.5% had
never attended school, 83.0% were unemployed, and 25.2% of the
respondents travelled more than three hours to the hospital. The
majority (68.5%) had disclosed their status to someone other than
the health care worker. More than a quarter (30.9%) faced some
form of stigma and discrimination because of their HIV positive
status. Patients had been taking ART for a median of 24 months
(range 4 to 48). The first line treatment regimens based on
2NRTIs+1NNRTI (Non/Nucleoside Reverse Transcriptase In-
hibitor) were used by almost all patients (99.4%). Interestingly,
none of the respondents were taking any traditional medicine with
ART for HIV treatment. All respondents identified the trade
names, dosage, and frequency of pills and all understood the
notion of adherence. The majority of the respondents had positive
perceptions of ART treatment and maintaining adherence; for
example, 95.2% perceived that even after feeling better, patients
should not stop taking ART medication.
Adherence in this study is encouraging with 282 (85.5%)
respondents reporting they had not missed a single dose in the
previous four weeks. When asked why they had missed their pills,
the most commonly reported reasons were transport costs (64%);
pills running out (62%); not wanting other people to notice (62%);
wanting to avoid side-effects (58%); and busy with other things
(48%) (Table 1).
Factors Associated with Adherence to ART
The univariate analysis found that 24 variables were signifi-
cantly associated with adherence (Table 2), although of these only
ten remained significant in the final multivariate logistic regression
model: patients who had not disclosed HIV status to anyone other
than health workers (OR=17.99, p = 0.014), who drank alcohol
(OR=12.89, p =,0.001), were female (OR= 6.91, p = 0.001),
illiterate (OR= 4.58, p = 0.015), had a regimen side-effect
(OR=6.04, p = 0.025), duration of ART started # 24 months
(OR=3.18, p = 0.009), travelled more than 1 hour to hospital
Adherence to Antiretroviral Treatment
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(OR= 2.84, p = 0.035) were significantly more likely to be non-
adherent. Similarly, patients who thought that HIV would
disappear after ART (OR=6.82, p= 0.008), that distance affects
ART adherence (OR =15.33, p = 0.008), that you could stop
taking the medicine once you felt better (OR= 6.43, p = 0.011), or
that HIV was preventable by taking regular ART (OR=4.31,
p = 0.003) were significantly more likely to be non-adherent.
The following were significant in the univariate analyses but
were not found to be so in the multivariate analysis: being
unemployed, missing scheduled hospital visit, method of travelling
to hospital, age # 35 years, number of pills taken per day, feeling
stigmatised or discriminated against, knowing that ART caused
problems and side-effects, and that treatment needs to be
continued even when feeling better or weight has been gained.
There was also no significant difference in the multivariate
analyses between those patients who did or did not know that
ART prevents HIV/AIDS progression; that ART did not cure
AIDS; and that forgetting ART can cause problems.
Qualitative results. The results of the in-depth interviews
complemented the survey and shed further light on its findings.
The thematic analysis suggested a range of factors which
negatively influenced adherence to ART.
Perception About ART
Perception is concerned with people’s beliefs that they can exert
control over their own motivation, thought processes, emotional
states and patterns of behaviour. However, negative perceptions
whether the efficacy of ART and its effects and could act as
barriers and be preventing adherence. For example, one
participant discussed that:
Rural people do still not believe this medicine [ART] work for HIV
patients. HIV people will die eventually either taking or not taking
ART. Why should I die by taking these malicious pills? They stopped
taking medicine after initiating treatment (P- 12, Female, Far-western).
Religion and Rituals Obstacles
People live in a community and need to abide by their local
traditional and religious rituals, which can influence adherence to
ART. For example, a Muslim reported:
I stopped my morning ART during Ramadan …I was sick and went to
consult the doctor and he told me not to stop at any time….now I am
taking medicine when fasting (P - 16, Female, Highway).
Health care providers noticed that some PLHIV did not take
their morning ART because their culture required fasting from
sunrise and to sunset.
Some Muslim patients have changed their [ART] routine due to their
festival and they left out the morning dose. This is due to their culture (P
- 25, Counsellor, Highway).
A doctor also stated that in both Hindu and Muslim festivals
women fast adding:
I am not blaming all my patients but a few Hindu women during Teej
and Muslim patients in Ramadan have problems taking medicine … a
few Muslim patients did not take medicine in the morning because of
Table 1. Socio-demographic characteristics of the sample.
Variables N (%)
Sex
Female 142 (43.0)
Male 188 (57.0)
Level of education
Never attended school 127 (38.5)
Primary school 122 (37.0)
Secondary school (SLC) 44 (13.3)
College level and above 37 (11.2)
Unemployed 274 (83.0)
Disclosed HIV status 226 (68.5)
Experienced stigma/discrimination 102 (30.9)
Use alcohol 65 (19.7)
Used memory aid
Watch/mobile alarm 249 (75.5)
Do not have any memory aids 66 (20.0)
Written schedule 12 (3.6)
Text message by health worker 3 (0.3)
Having family support
No one 141 (42.7)
Spouse 130 (39.4)
Family members 51 (15.5)
Best friend 8 (2.4)
ART initiated (months)
Median (IQR)
24.0 (12 to 36)
Regimens
First line 328 (99.4)
Second line 2 (0.6)
Time to reach hospital
.1 hour 194 (58.8)
#1 hour 136 (41.2)
Self-reported adherence
Four days adherence 312 (94.5)
One week adherence 307 (93.0)
Four weeks adherence 252 (85.5)
Reasons for missing medication (N=48)
(multiple responses allowed)
Not having travel fare 32 (64.0)
Pills ran out 31 (62.0)
Not wanting other people to notice 31 (62.0)
Wanted to avoid side-effects 29 (58.0)
Were busy with other things 24 (48.0)
Felt sick or ill 18 (36.0)
Nepal strike (transportation blocked) 17 (34.0)
Simply forgot 17 (34.0)
Were away from home 13 (26.0)
Alarm not working /slept in 8 (16.0)
Taking alcohol at specific time 5 (10.0)
Problems to take pills at specified time 5 (10.0)
Fasting 2 (4.0)
Family quarrel 1 (2.0)
doi:10.1371/journal.pone.0035547.t001
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Table 2. Potential factors influencing adherence to ART.
Variables
Adhere
N (%)
Non-adhere
N (%)
Univariate
OR p
Multivariate
OR p
Alcohol intake
Yes 40 (61.5) 25 (38.5) 6.58 (3.41 to 2.69) , 0.001 12.89 (3.97 to 41.85) ,0.001
No 242 (91.3) 23 (8.7)
Drug side-effects
Yes 195 (81.9) 43 (18.1) 3.84 (1.47 to10.02) 0.002 6.04 (1.25 to29.08) 0.025
No 87 (94.6) 5 (5.4)
Occupation
Unemployed 229 (83.6) 45 (16.4) 3.47 (1.04 to 11.60) 0.043
Employed 53 (94.6) 3 (5.4)
Distance to travel hospital
. one hours 159 (82.0) 35 (18.0) 2.60 (1.27 to 5.31) 0.009 2.84 (1.08 to 7.49) 0.035
# one hours 123 (90.4) 13 (9.6)
Missing schedule visit
Yes 139 (80.3) 34 (19.7) 2.50 (1.29 to 4.86) 0.005
No 143 (91.1) 14 (8.9)
Means to travel hospital
On foot 64 (76.2) 20 (23.8) 2.43 (1.29 to 4.61) 0.006
By vehicle 218 (88.6) 28 (11.4)
Duration of ART started
#24 months 162 (81.8) 36 (18.2) 2.22 (1.11 to 4.45) 0.024 3.18 (1.34 to 7.55) 0.009
.24 months 120 (90.9) 12 (9.1)
Education
Illiterate 100 (78.7) 27 (21.3) 2.34 (1.26 to 4.35) 0.007 4.58 (1.34 to 15.71) 0.015
Literate 182 (89.7) 21 (10.3)
Age
# 35 years 152 (81.7) 34 (18.3) 2.08 (1.07 to 4.04) 0.031
.35 years 30 (90.3) 14 (9.7)
Number of pills per day
. Three tablets 126 (80.8) 30 (19.2) 2.06 (1.09 to 3.87) 0.024
# Three tablets 156 (89.7) 18 (10.3)
Disclosure of status
No 82 (78.8) 22 (21.2) 2.06 (1.11 to 3.85) 0.023 17.99 (1.81 to 78.48) 0.014
Yes 200 (88.5) 26 (11.5)
Gender
Female 114 (80.3) 28 (19.7) 2.06 (1.06 to 4.06) 0.022 6.91 (2.31 to 20.67) 0.001
Male 168 (89.4) 20 (10.6)
Stigma and discrimination
Yes 81 (79.4) 21 (20.6) 1.93 (1.03 to 3.61) 0.039
No 201 (88.2) 27 (11.8)
Knowledge on forgetting ART cause problems
No/don’t know 6 (54.5) 5 (45.5) 5.35 (1.56 to 18.29) 0.014
Yes 276 (86.5) 43 (13.5)
HIV will disappear after ART
Yes/don’t know 5 (55.6) 4 (44.4) 5.04 (1.31 to 20.95) 0.027 6.82 (1.64 to 28.31) 0.008
No 277 (86.3) 41 (13.7)
ART cause side-effects
Yes 193 (82.1) 42 (17.9) 3.23 (1.32 to 7.87) 0.005
No/don’t know 89 (93.7) 6 (6.3)
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Ramadan. They told me if they drink water during the day this is totally
sinful (P - 27, Doctor, Kathmandu).
Religious constraints would seem to remain the most significant
barrier to adherence and where this is compounded by
unsympathetic family circumstances as discussed below, non-
adherence may be even more likely to occur.
Alcohol Intake
Alcohol intake was mentioned by PLHIV as contributing to
non-adherence. Some stated that at festival times they were
expected to drink alcohol and that this caused difficulty with
remembering their medication routine. A male disclosed that:
I need to attend parties and drink during festival times, when I drink
alcohol; I have great difficult in taking my night dose [of ART]. I
missed it many times (P - 13, Male, Hill).
Health care providers also agreed that some patients had
reported missing ART due to alcohol consumption.
Lack of family support
Lack of family support acted as a barrier to adherence and
family arguments stopped them from taking medication, as one
female participant explained:
I skipped two doses because of a family quarrel my family did not allow
me to visit hospital (P - 14, Female, Highway).
Some professionals also noted that patients without family
support had lower adherence levels, e.g.:
One patient … skipped medicine due to no one getting her medicine from
the hospital for her. She was bed-ridden, but family members did not
bring medicine. Because the pills ran-out and no one helped her, she
skipped some doses [of ART] (P - 18, Counsellor, Far-western).
Conversely, one female participant narrated how her family
helped her,
…I often forgot to take ART, my daughter ask me, mummy, have you
taken your medicine today? …. She reminds me. Almost all the time she
[daughter] brings a glass of water and pack of medicines (P - 12,
Female, Far-western).
Thus, the combination of difficulty of accessing hospital and an
unhelpful family can negatively affect adherence whereas family
support enhance adherence.
Table 2. Cont.
Variables
Adhere
N (%)
Non-adhere
N (%)
Univariate
OR p
Multivariate
OR p
Perception that if patients feel well, they can stop
taking their ART
Yes/don’t know 7 (43.8) 9 (56.3) 9.07 (3.20 to 25.73) ,0.001 6.43 (1.53 to27.04) 0.011
No 275 (87.6) 39 (12.4)
Distance affects ART adherence
Yes 232 (83.5) 46 (16.5) 4.96 (1.17 to 21.09) 0.010 15.33 (2.06 to 14.25) 0.008
No/don’t know 50 (96.2) 2 (3.8)
ART recipients will get sicker if they stop taking their
medication
No/don’t know 13 (59.1) 9 (40.9) 4.78 (1.92 to 11.91) 0.001
Yes 269 (87.3) 39 (12.7)
ART prevents HIV/AIDS disease progression
No/don’t know 27 (64.3) 15 (37.5) 4.29 (2.07 to 8.89) 0.015
Yes 255 (88.5) 33 (11.5)
ART cure on HIV
Yes/don’t know 11 (61.1) 7 (38.9) 4.21 (1.54 to 11.47) 0.009
No 271 (86.9) 41 (13.1)
ART must continue even after feeling better
No/don’t know 8 (61.5) 5 (38.5) 3.98 (1.25 to 12.74) 0.033
Yes 274 (86.4) 43 (13.6)
ART should not stop after gaining weight
No/don’t know 9 (64.3) 5 (35.7) 3.53 (1.13 to 11.02) 0.046
Yes 273 (86.4) 43 (13.6)
HIV is preventable by taking regular ART
Yes/don’t know 56 (76.7) 17 (23.3) 2.21 (1.14 to 4.28) 0.022 4.31 (1.67 to 11.13) 0.003
No 226 (87.9) 31 (12.1)
doi:10.1371/journal.pone.0035547.t002
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Economic Constraints
Money emerged as the most commonly mentioned barrier to
adherence, as most respondents reported economic worries related
to the cost of (a) transport, (b) prescription, (c) diagnosis, and (d)
food. Transport costs emerged as a key theme and PLHIV often
did not have enough money to go to the health facility to get their
repeat prescription (‘refill’). One interviewee reported;
… I missed my medication twice because of money. I need to find 600
rupees (,£5) for bus fare every month to refill ART. How can I
afford this [cost]? I do not have any alternative except missed treatment
(P – 2, Male, Highway).
Health care providers also concurred with this. This may
remain a major reason why some individuals may not be able to
come to the health facility to refill their prescriptions.
Stigma and Discrimination
Most participants had experienced some form of discrimination,
and HIV-related stigma (or fear of stigma) was identified by the
majority of interviewees as influencing adherence behaviour
especially among women. For example:
I have not taken my medication two occasions because relatives and
neighbours were in my house. I did not get time to take out medicine
from my drawer…… I have frequent problem to hide my medicine from
others because I am living in a rented single room. ….Oh! I cannot tell
anyone (P - 5, Female, Kathmandu).
Due to the fear of being victimised and/or rejected by their
family or community, this generated a fear of exposure, which in
itself affected adherence, e.g.:
I am worried about meeting my neighbours in hospital for refills
[ART]. All the time I worry: ‘‘How can I hide from these people?’’ One
day I did not refill my ART due to bumping into relatives (P - 4,
Female, Kathmandu).
Some care providers noted that PLHIV selected ART sites
where no one would know them:
Many patients still prefer to visit the distant hospital; they are not ready
to go nearby. This all about the fear of [disclosure to] other people (P -
20, Counsellor, Kathmandu).
A doctor added:
Clients are still stigmatized …. they fear other people …’What do they
think?’, ‘What do they say?’ clients are not ready to take medicine in
front of other people …they choose the alternative and skip medication
(P – 27, Doctor, Kathmandu).
Distance
Nepal’s large rural hinterland combined with a limited number
of ART sites was perceived to have a negative effect on adherence.
Distance was a big concern particularly outside Kathmandu. Long
travelling distance to and from ART sites remains one of the most
challenging adherence issues and it was frequently discussed by
both PLHIV and providers:
I need to walk more than one and half days to refill my medicine [ART]
…this is very difficult at my age, not once a year, but every month (P -
1, Male, Highway).
Staffs also considered distance to be a big hurdle to adherence,
as one counsellor discussed,
[PLHIV walk to] … this hospital is more than two days on foot. Oh!
Some clients have to cross so many small and medium rivers to come to
the hospital. No bridge. I do not think it is fair to blame them for
defaulting (P - 18, Counsellor, Far-western).
Similarly, policy-makers agreed that distance and centralised
ART-providing institutions limited adherence:
Treatment services are located in a limited number of central hospitals,
which is a major problem for HIV positive people seeking services.
That’s definitely limiting their adherence HIV treatment service as is
still not reaching the people in need (P - 33, Policy level).
Thus the poor, and rural dwellers, who have difficulty travelling
long distances for ART, may benefit from nearby ART facilities.
Although this may be offset by the fear of disclosure, thus causing
them to continue to travel to more distant sites.
Short Period of Medicine Prescription
Having few ART institutions is itself a barrier to getting repeat
prescriptions on time as well as different prescribing policies in
different hospitals. Some clinicians prescribe ART drugs for one
month, others up a maximum of two months. ART prescription
practice is not associated with a single issue but it was linked with
multiple factors i.e. cost, transport facilities, time. Some inter-
viewees stated that;
Doctors prescribed ART only for a month. This is very short
time….every month to refill ART is extremely difficult to adhere this
medication (P - 5, Female, Kathmandu).
However, rural clinicians mostly prescribed up to two months of
ART, for example:
I have to visit this clinic every two months to refill medicine. I have to
arrange money and need to walk long distance which is very hard; not
only for me but most of the PLHIV [from hill districts]. To refill ART
at every two months is the main problem for me sir (P - 10, Male,
Hill).
Insufficient Pills in Shell Pack Bottles
There can be a discrepancy between the labelling and the
contents of packages. Insufficient number of pills in a bottle or
pack was raised as a barrier to adherence. Sometimes there were
fewer pills in a pack than stated on the label. A health care
provider reported that some patients had been supplied with an
inadequate number of pills and hence missed one or two doses.
One patient complained that the label seal packed bottle did not contain
the complete number of pills according to label ( = 60) he complained to
me that there were just 58 pills and he did not get one dose according to
the schedule of ART refill (P - 19, Counsellor, Hill).
Adherence to Antiretroviral Treatment
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Counting pills in front of patient may be necessary to ensure
that the patient is given the full dose of medicines prescribed and
would avoid incomplete supplies.
Strikes (Transportation Blocked)
Nepal’s political situation was very volatile at the time of the
study, which led to frequent and unpredictable strikes. This often
meant that main roads were blocked and this obstacle to transport
impeded ART adherence, for example:
Unexpected strikes are in fashion at the moment….bus strikes, and last
time even the hospital was on strike for a week…. How can we take
regular medicine? … ‘Think about Nepal’s geography and distance,
how can all ART recipients receive ART medicine without missing
any?’ (P - 5, Female, Kathmandu).
Service providers also agreed that, due to frequent and
unexpected roadblocks, PLHIV had no alternative than to stop
medication or miss some doses of their medicine.
Side-effects of ART
ART side-effects were one of the most discussed themes in this
study. Most participants had experienced side-effects, which
increased non-adherence, e.g.:
ART caused a problem rather than good health. I could not tolerate the
pain and I stopped for a while (P - 9, Male, Highway).
Similarly, a female PLHIV found that ART:
… has given more side-effects for me such as vomiting, herpes/ zoster
and skin rashes. I have lost my sight in my right eye and my left eye also
has poor vision (P - 12, Female, Far-western).
Doctors agreed that side-effects led some patients to stop taking
ART. These common side-effects included vomiting, diarrhoea,
body pain, skin rashes and reduced body fat.
Gender and Adherence
Due to socio-cultural and economic restrictions put upon
women in Nepal, women found it far more difficult to adhere to
their ART medication than their male counterparts did. Most of
the health-care providers mentioned that men had better
adherence than women did. A care provider argued that:
Male adherence is better, they [male] do not need to be accompanied to
refill prescription, they can travel easily, most of them disclosed [HIV],
they can easily understand, whereas women had more difficulties in
understanding. Also treatment usually start when they (women) were
bedridden (P - 22, Counsellor, Highway).
Discussion
The rate of adherence in our sample was significantly higher
(85.5%) than has been observed in other studies in Asian
developing countries that also relied upon self-report [22–24]. A
meta-analysis found that patients in Africa had better adherence
than their North-American counterparts with pooled estimates of
77% of participants achieving adherence in the African studies
and 55% of participants in the North-American studies [9]. The
possible explanation for greater adherence in our study might be
due to using (a) self-reported adherence; (b) only first-line
regimens; (c) strict adherence counselling sessions pre and post
ART; and (d) recruiting participants through clinics so that only
active patients participated (patients who actually went to the
clinic).
Many factors identified in this study are consistent with the
literature from both developed and developing countries. In this
study, females reported poorer adherence than males as
corroborated by care providers. This finding is unique since very
few studies have reported that men were more likely to adhere to
ART than women [25–27]. This is an important finding in the
Nepalese context, as women are treated differently and unequally
due to socio-cultural and economic factors. Nepalese women are
recognized to be ill by family members only when they are
bedridden and the head of the household (usually their husband or
mother-in-law) decides that they are seriously ill. Women in this
study were less likely to disclose their HIV status (66.2% vs 70.2),
and were more vulnerable to discrimination by others compared
to male PLHIV (45.1% vs 20.2%), both of which could be used to
explain this finding. Different forms and types of HIV-related
stigma exist such as self-stigma (self-blame or condemnation),
perceived stigma (fear of stigma associated with disclosing HIV
status) and enacted stigma (gossip, rejection, discrimination) and
these were barriers to adherence [28,29]. Our qualitative findings
also revealed that stigma (or fear of stigma) was identified by the
majority of interviewees as impeding adherence behaviour
particularly among women. This will become an increasing
problem because of increasing female infection rates in Nepal,
but currently the Government still lacks programmes targeted to
test, treat and improve treatment adherence for women [30].
Nepali women require special and urgent consideration because of
their socio-cultural and sexual subordination [31,32]. Additionally,
women are most often responsible for care of the household and
children, and as a consequence these practical barriers may
adversely affect adherence among women more than among men
[33]. Thus, interventions that focus on women taking ART may
benefit from paying special attention to the multiple life demands
that can interfere with their ability to refill medication or obey
specific instructions from their care provider.
Other adherence barriers raised during the interviews included
local culture, especially religious activities and festivals such as
‘‘Teej’’ for Hindu women and ‘‘Ramadan’’ for Muslims. Religious
beliefs are complex concepts and are part of the basic assumptions
which shape people’s identities and strongly affect their decision-
making such as taking medication on fasting days [34,35]. It is
difficult to see how this could be overcome but our findings
reinforce the importance of considering the religious and spiritual
beliefs of PLHIV as part of medical care. It has been suggested
that incorporating discussions about spiritual beliefs into adher-
ence counselling could foster adherence [36]. As a result, patients
could be motivated by seeing improvements in their health
condition to continue adherence all the time. It is believed that
most religions give freedom to eat on fasting day especially to the
sick, children, and older people. This message needs to be
reinforced during counselling.
Similarly, being illiterate, drinking alcohol and starting ART
within the past two years were all associated with increased
likelihood of non-adherence to ART in our study and similar
findings have been reported elsewhere [25,37–41]. Education may
impact on adherence in several ways including facilitating
communication with health care providers, increasing retention
of information provided by health workers and thereby enhancing
adherence to ART medication. It is possible that patients with
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limited literacy might be reluctant to ask others for the kind of help
they need to take their medicines correctly [42]. Better-educated
people convinced of ART efficacy, perhaps as a result of
educational programmes, show a propensity towards better
adherence [43]. A meta-analysis of drinking alcohol showed that
individuals who drank alcohol had a reduced adherence to ART
of between 40% to 50% [40]. Therefore, adherence interventions
among females, those new to ART, illiterate patients and patients
who drink alcohol need to consider these factors when reinforcing
continuing adherence practices [33,44]. It may be necessary to
schedule follow-ups that are more frequent, monitor adherence
more closely and ensure that education and discussions take place
in a safe environment.
Patients’ beliefs, knowledge and expectations regarding treat-
ment strongly influence their medical decision making [45]. Our
findings show that a few patients believed that ART cured HIV or
were unclear about how long they should take ART. Every ART-
prescribed patient needs to understand that with appropriate
treatment and continuing adherence HIV/AIDS is now a
manageable chronic disease [2,46]. Therefore, every patient needs
to understand the importance of adherence because inaccurate
information and misconceptions towards the disease and treat-
ment regimens are associated with poor therapeutic outcomes [47]
that in turn may be an impediment to achieving optimal levels of
adherence [33,48]. PLHIV who believe in the efficacy of ART are
more likely to adhere [49]. Hence, care providers should continue
to educate PLHIV and their families and develop intervention
strategies that address the local context in order to encourage
people to adhere to ART.
Although ART drugs have been provided free of charge since
2004 in Nepal, ART associated costs are not (including transport,
prescription, procuring food and diagnostic testing) and remain
barriers. In addition, 62% of respondents cited pills running out as
a second main reason for skipped medication. These ART-
associated costs have been found to be a barrier to adherence in
other Asian developing countries [13] and many other developing
countries [9,50–52]. A study in India found that almost all the
participants discussed the cost of ART as a barrier, with many
reporting drug holidays, turning to family and or friends or taking
drastic measures (i.e. selling jewels, property) for financial
assistance [53]. A study in Botswana showed that adherence was
higher when cost was not an obstacle and poor patients were able
to achieve excellent rates of adherence when they had access to
free laboratory monitoring and subsidized ART [54]. This is a
useful finding and it is important that policy makers use this
information to introduce social policy which includes subsidies for
transport, and other costs associated with ART. Addressing the
ART-associated cost issue of non-adherence in Nepal may
therefore require a somewhat different approach to solutions
applied in developed countries where financial issues are not such
a major concern.
In the in-depth interviews, participants raised the issue that
physicians prescribed ART for periods that were too short thus
increasing costs associated with transportation to collect medica-
tion. This has also been documented elsewhere [55,56]. Patients
were worried and reported that to refill medicines every month
caused difficulties in maintaining adherence. Thus, the Govern-
ment of Nepal needs to consider carefully the amount of medicine
that is prescribed on each occasion as well as subsidizing travel
costs. To make available ART collection points in local health
institutions may also help to manage this short period between
refills. Once these have been implemented, further research will
need to be focused on the effectiveness of these and other possible
interventions to decrease barriers related to transportation costs.
In addition, non-disclosure of HIV status to anyone except
health workers was associated with poorer adherence in our study
and has been documented elsewhere too [9,13,57,58]. Studies
have shown that HIV disclosure is necessary to facilitate
adherence to ART [59] and PLHIV who did not disclose to their
family or peers had poorer adherence than those who disclosed
their status [9,59]. Our findings suggest that disclosure is an
important issue, which should be discussed during the counselling
sessions. For those who have not disclosed, providers should
explain the importance of disclosure for the success of ART.
Skipping and stopping doses were attributed to fear that other
people would discover their HIV status. Stigma and discrimination
were not found to be significant influencing factors in the
multivariate analysis, but in the in-depth interviews the majority
of participants (seven female vs. four male) raised as this as a
barrier to adherence. Patients were too embarrassed to take their
medication in front of others, and concerned about privacy when
collecting repeat prescriptions and taking medication; these
worries increased non-adherence and have also been found in
other studies outside Nepal [13,58,60]. One study stated that
PLHIV were unwilling to seek treatment at the nearest health
facility because of fear of stigmatization [61] and this same issue
was discussed in our study too. Hence, policy makers should
encourage a supportive environment where PLHIV do not need to
worry about stigma and discrimination but talk openly in order to
facilitate adherence. In addition, patients should also be taught
strategies on how to handle taking pills in secret to increase
adherence to their medication.
Distance to treatment centre is of great concern to PLHIV and
one of the key factors preventing adherence in this sample.
Patients who travelled more than one hour to hospital were more
likely to be non-adherent and this was also discussed in the in-
depth interviews. Participants stated that although patients were
willing to take ART they became non-adherent because of
difficulties in reaching the treatment centres due to unexpected
transport and other strikes; long travel distance; geographical
difficulty including lack of transportation services in many remote
areas; and the seasonal deterioration of poorer roads during the
rainy season. This has also been found to be the case with respect
to maternity services in Nepal [62]. Others have also found that
travel time and access to treatment centres were barriers to ART
adherence [52,63] and that better access to care was significantly
associated with optimal adherence [13]. Patients who are from
rural areas have difficulties in travelling long distances and finding
their travel costs, and have most to gain from nearby ART
facilities. Although this benefit may be offset by patients who fear
of disclosure and worry about others finding out, are still travelling
to more distant sites. Thus, any new policy will need to address this
issue and improve access to medical care services by integrating
ART treatment into the mainstream of health care rather than
concentrating treatment in a limited number of ART centres,
which may be hard to reach for many patients.
ART regimens have toxicities and adverse side-effects that vary
from mild to severe and acute to chronic, which can prevent
adherence [64]. Our study revealed that patients who had side-
effects were more likely to be non-adherent and this has also been
reported from several studies conducted in both developed and
developing countries [9,13,65]. Similarly, patients who have been
on ART for less than two years were more likely to be non-
adherent, but there is no clear indication for why this is the case.
There may not be a single reason behind non-adherence of this
group but side-effects may be one of the possible explanation
because the literature shows that up to 45% of ART prescribed
patients discontinue one or more of the drugs within a year of
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starting due to side-effects and the inconvenience of the regimen
[66]. Therefore, there is a need for continuing follow-up, clinical
support and counselling for patients on ART in the early years of
treatment as well as providing instructions on how to cope with
side-effects [67]. Health care providers should review possible
anticipated side-effects and develop treatment plans that either
prevent, or at the very least, reduce the likelihood of side-effects
happening. These may be tackled by strengthening institutional
support, including clinicians and other health professionals
informing patients in advance what side-effects to expect and
how they might be managed, as well as prescribing antiemetic or
anti-diarrheal agents to alleviate these side-effects. In addition
interviewees raised the issue of discrepancies between the labelling
and contents of packages of pills. Therefore, counting pills in front
of patients is necessary to ensure complete dose of medicines
prescribed to avoid incomplete supplies.
Participants discussed the twofold nature of social support
systems: lack of support as a barrier to adherence and, when
actually in place, as a facilitator of adherence [68]. Some people
were accepting and supportive whilst others overtly or subtly
distanced themselves from people with HIV. In this study, family
members reminded 57.3% respondents of their medication
although this was not significantly associated with adherence.
Furthermore, findings from the in-depth interviews highlighted
that family support increased the likelihood of patients maintain-
ing optimal adherence. Others have also found that social and
family support, communication and access to care that anticipate
patients’ individual needs play an important positive role
[9,13,69], and family acts as a facilitating factor of adherence
primarily among children and women [70]. A meta-analysis
reported that adherence is 1.74 times higher in patients from
cohesive families [71] whereas absence of this is a factor leading to
poor adherence [72]. Therefore, health care providers should
continue discussions with new starters and follow up individuals
without support to find an alternative source of help to foster
adherence.
Strengths and Limitations of the Study
The main strength of our study is that it is the first to examine
adherence to ART in Nepal. Using a mixed-methods approach
across multiple sites allowed for triangulation through synthesising
data from multiple sources of informants. Mixed methods assisted
in highlighting important factors, which may not be effectively
explored by using only a single method. Our study had an
extremely high response rate. No one who was asked to participate
refused to do so. We think this is because HIV research is in its
infancy in Nepal and this was the first ever research project for this
population of PLHIV. Moreover, it offered an opportunity for
PLHIV to talk about living with HIV in a society where this is
generally problematic.
However, the study does have some limitations. Due to financial
constraints adherence was assessed through a self-reporting
adherence questionnaire and not other more objective tools such
as electronic pill caps, pills counts, and biological methods
(patients’ viral load and CD4 count) that should be priorities for
future studies. Despite concerns that self-reporting may overesti-
mate adherence, it has been demonstrated elsewhere that self-
reported adherence has consistently correlated with viral load and
clinical outcomes in HIV treatment [73–75], as well as improved
quality of life [74], and has been deemed a robust and appropriate
indicator of adherence [76].
The second major limitation of this study is that the respondents
consisted only of patients who actually went to ART clinics. We
did not interview people who were picking up ART drugs for
someone else and this means that we may have missed patients too
sick to attend appointments. Additionally, those who defaulted
from the ART service were not interviewed. Thus our participants
were motivated and well enough to attend ART clinics, this may
also explain why all could say at least the trade names of the ART
they were taking. We would recommend that future researchers
should try to trace defaulting ART patients and identify challenges
perceived by these patients.
This study is a cross-sectional study, which measured adherence
at a single time point. However, adherence is a dynamic process
that may change over time; thus, it may be that multiple contacts
with respondents could have provided more useful information
than a single interview. Therefore, longitudinal studies with a
wider range of respondents and the use of a combination of
adherence assessment tools are also necessary in this setting to
understand adherence over time and to explore the factors that
influence adherence to ART in the longer term, which could most
likely reduce the risk of overestimation.
Conclusion
Adherence (85.5%) in Nepal is sub-optimal (defined as less than
95%) but this finding is similar to other Asian developing
countries, as well as being better than has been measured by
self-report in many developed counties. There are a range of
reasons for failing to adhere to ART, including drinking alcohol,
having drug side-effects, long distance to travel to hospital, being
illiterate, non-disclosure of HIV status, being female, lack of
knowledge and negative perceptions towards ART. The key
reason for skipping ART given was travel fare problems
presumably in order to collect ART, followed by pills running
out and wanting to avoid the side-effects. Qualitative findings also
added that religious or ritual obstacles, embarrassment about
taking medication in front of others, financial constraints, and
transport problems including strikes and adverse side-effects were
important factors in non-adherence. Priorities should be given to
improving adherence by providing regular follow-up, increasing
patients’ awareness of the ART treatment, including its benefits
and side-effects, eliminating problems of access and alleviating the
impact of cost. Policy makers need to be aware of these key
barriers and consider social policy which encourages patients to
achieve optimal adherence.
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